medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2014, Number 1

<< Back Next >>

Ann Hepatol 2014; 13 (1)

Stem cell and hepatocyte proliferation in hepatitis C cirrhosis and hepatocellular carcinoma: transplant implications

Behnke MK, Reimers M, Fisher RA

Language: English
References: 37
Page: 45-53
PDF size: 155.39 Kb.


ABSTRACT

Background. The liver possesses two distinct mechanisms for healing. Wound healing via hepatic stem cells recapitulates early development (hepatoblast proliferation), while liver regeneration resembles late embryonic growth (hepatocyte proliferation). Loss of control over both of these processes have been proposed as mechanisms that may contribute to poor outcomes in HCC. Material and methods. We used microarray gene expression profiles to examine the involvement of hepatic stem cell and hepatocyte proliferation markers and regulators in HCV-induced cirrhosis and HCC. We compared 30 cirrhosis and 49 HCC samples to 12 disease-free control livers. Results. Cirrhosis and HCC expressed markers of stem cell. Inhibitors of hepatocyte proliferation (HP) were highly expressed in cirrhosis. Loss of these HP inhibitors in HCC patients was associated poor prognosis (94 vs. 38% 2-year recurrence- free survival, p = 0.0003). Principal Components Analysis discriminated cirrhotic and HCC tissues, and HCC patients with poor (‹ 2 year) vs. good (› 2 year) recurrence-free survival. Loss of CDH1 expression correlated with up-regulation of hepatocyte proliferation promoters MET and YAP1. CDH1, MET, and YAP1 were independent predictors of recurrence-free survival by Cox regression when corrected for tumor stage (p ‹ 0.0001). Conclusion. HCV-cirrhosis is characterized by proliferation of liver stem cells and inhibition of hepatocyte proliferation. HCC tumors in which this pattern persists have superior outcomes to those which acquire a hepatocyte proliferation signature. Genes in this signature should be studied further for potential as tissue or serum biomarkers for patient risk stratification. CDH1 and MET are candidates for personalized therapies with targeted pharmaceutical agents.


REFERENCES

  1. Everhart JE, Ruhl CE. Burden of digestive diseases in the United States Part III: Liver, biliary tract, and pancreas. Gastroenterology 2009; 136: 1134-44.

  2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-17.

  3. Bruix J, Sherman M. Management of hepatocellular carcinoma: An update. Hepatology 2011; 53: 1020-2.

  4. Singal AG, Conjeevaram HS, Volk ML, Fu S, Fontana RJ, Askari F, Su GL, et al. Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev 2012; 21: 793-9.

  5. Sterling RK, Wright EC, Morgan TR, Seeff LB, Hoefs JC, Di Bisceglie AM, Dienstag JL, Lok AS. Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. Am J Gastroenterol 2012; 107: 64-74.

  6. Shirakawa H, Kuronuma T, Nishimura Y, Hasebe T, Nakano M, Gotohda N, Takahashi S, et al. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer. Int J Oncol 2009; 34: 649-56.

  7. Villanueva A, Hoshida Y, Toffanin S, Lachenmayer A, Alsinet C, Savic R, Cornella H, Llovet JM. New strategies in hepatocellular carcinoma: genomic prognostic markers. Clin Cancer Res 2010; 16: 4688-94.

  8. Llovet JM, Paradis V, Kudo M, Zucman-Rossi J. Tissue biomarkers as predictors of outcome and selection of transplant candidates with hepatocellular carcinoma. Liver Transpl 2011; 17: S67-71.

  9. Yamashita T, Forgues M, Wang W, Kim JW, Ye Q, Jia H, Budhu A, et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 2008; 68: 1451-61.

  10. Yamashita T, Ji J, Budhu A, Forgues M, Yang W, Wang HY, Jia H, et al. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 2009; 136: 1012-24.

  11. Villanueva A, Chiang DY, Newell P, Peix J, Thung S, Alsinet C, Tovar V, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008; 135: 1972-83, 1983.e1-11.

  12. Llovet J. Emerging agents for the medical therapy of hepatocellular carcinoma. Gastroenterol Hepatol (N Y) 2007; 3: 600-2.

  13. Sanyal AJ, Yoon SK, Lencioni R. The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist 2010; 15: 14-22.

  14. Behnke M. Growth gone awry: exploring the role of embryonic liver development genes in HCV induced cirrhosis and hepatocellular carcinoma (doctoral dissertation). 2012.

  15. Avruch J, Zhou D, Fitamant J, Bardeesy N. Mst1/2 signalling to Yap: gatekeeper for liver size and tumour development. Br J Cancer 2011; 104: 24-32.

  16. Fisher R, Maroney T, Fulcher A, Maluf D, Clay J, Wolfe L, Dawson S, et al. Hepatocellular carcinoma: Strategy for optimizing surgical resection, transplantation and palliation. Clin Transplant 2001; 16: 52-8.

  17. Mas VR, Maluf DG, Archer KJ, Yanek K, Kong X, Kulik L, Friese CE, et al. Genes involved in viral carcinogenesis and tumor initiation in HCV-induced HCC. Mol Med 2009; 15: 85-94.

  18. Archer KJ, Mas VR, O’Brien TR, Pfeiffer R, Lum NL, Fisher RA. Quality assessment of microarray data in a multi-center study. Diagn Mol Pathol 2009; 18: 34-43.

  19. Wurmbach E, Chen YB, Khitrov G, Zhang W, Roayaie S, Schwartz M, Fiel I, et al. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 2007; 45: 938-47.

  20. Reimers M, Weinstein J. Quality assessment of microarrays: Visualization of spatial artifacts and quantitation of regional biases. BMC Bioinformatics 2005; 6: 166.

  21. Sandberg, R; Larsson O. Improved precision and accuracy for microarrays using updated probe set definitions. BMC Bioinformatics 2007; 8: 48.

  22. Behnke M, Reimers M, Fisher R. The Expression of Embryonic Liver Development Genes in Hepatitis C Induced Cir-rhosis and Hepatocellular Carcinoma. Cancers 2012; 4: 945-68.

  23. Pecina-Slaus N. Tumor suppressor gene E-cadherin and its role in normal and malignant cells. Cancer Cell International 2003; 3: 17.

  24. Xu CP, Ji WM, van den Brink GR, Peppelenbosch MP. Bone morphogenetic protein-2 is a negative regulator of hepatocyte proliferation downregulated in the regenerating liver. World J Gastroenterol 2006; 12: 7621-25.

  25. Zhou D, Conrad C, Xia F, Park JS, Payer B, Yin Y, Lauyers GY, et al. Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell 2009; 16: 425-38.

  26. Song H, Oh S, Oh HJ, Lim DS. Role of the tumor suppressor RASSF2 in regulation of MST1 kinase activity. Biochemical and Biophysical Research Communications 2010; 391: 969-73.

  27. Gloushankova NA. Changes in regulation of cell-cell adhesion during tumor transformation. Biochemistry (Moscow) 2008; 73: 742-50.

  28. Wang C, Yang W, Yan HX, Luo T, Zhang J, Tang L, Wu FQ, et al. Hepatitis B virus X (HBx) induces tumorigenicity of hepatic progenitor cells in 3,5-diethoxycarbonyl-1,4-dihydrocollidine- treated HBx transgenic mice. Hepatology 2012; 55: 108-20.

  29. Lee JS, Heo J, Libbrecht L, Chu IS, Kaposi-Novak P, Calvisi DF, Mikaelyan A, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006; 12: 410-6.

  30. Machida K, Chen CL, Liu JC, Kashiwabara C, Feldman D, French SW, et al. Cancer stem cells generated by alcohol, diabetes, and HCV. J Gastroenterol Hepatol 2012; 27: 19-22.

  31. Battaglia S, Benzoubir N, Nobilet S, Charmneau P, Samuel D, Zignego AL, Atfi A, et al. Liver Cancer-Derived Hepatitis C Virus Core Proteins Shift TGF-Beta Responses from Tumor Suppression to Epithelial-Mesenchymal Transition. PLoS ONE 2009; 4: e4355.

  32. Boyault S, Rickman DS, de Reyniès A, Balabaud C, Rebouissou S, Jeannot E, Herault A, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007; 45: 42-52.

  33. Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P, Minguez B, LeBlanc AC, et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 2008; 68: 6779-88.

  34. Chen X, Cheung ST, So S, Fan ST, Barry C, Higgins J, Lai KM, et al. Gene expression patterns in human liver cancers. Mol Biol Cell 2002; 13: 1929-39.

  35. Mas VR, Maluf DG, Archer KJ, Yanek K, Williams B, Fisher RA. Differentially expressed genes between early and advanced Hepatocellular Carcinoma (HCC) as a potential tool for selecting liver transplant recipients. Mol Med 2006; 12: 97-104.

  36. Al-Moundhri MS, Al-Nabhani M, Tarantini L, Baccarelli A, Rusiecki JA. The Prognostic Significance of Whole Blood Global and Specific DNA Methylation Levels in Gastric Adenocarcinoma. PLoS ONE 2010; 5: e15585.

  37. Sebova K, Zmetakova I, Bella V, Kajo K, Stankovicova I, Kajabova V, Krivulcik T, et al. RASSF1A and CDH1 hypermethylation as potential epimarkers in breast cancer. Cancer Biomark 2011-2012; 10: 13-26.




2020     |     www.medigraphic.com